Future Science Group
Supplementary Material.docx (139.54 kB)

Supplementary Tables: Supplementary Materials. The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark

Download (139.54 kB)
posted on 2021-11-29, 11:30 authored by Lars H Ehlers, Mark Lamotte, Mafalda C Ramos, Susanne Sandgaard, Pia Holmgaard, Evan C Frary, Niels Ejskjaer
Table S1: Baseline Characteristics.
Table S2: Treatment Effects – First Line.
Table S3: Adverse Events.
Table S4: Treatment effects for second/third line treatments (treatment policy estimand).
Table S5: Proportion of patients on preventive medication.
Table S6: Screening and patient management proportions.
Table S7: Sensitivity and specificity of tests.
Table S8 Annual treatment costs applied (DKK, AIP 2020, [20]).
Table S9 Cost Inputs for the CDM (Costs inflated to 2020 values, DKK).
Table S10: Utilities used in CDM.
Table S11: Scenario analysis results.
Table S12: Breakdown of costs (DKK, per average patient).


Funded by Boehringer Ingelheim